Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
CCR5 antagonist

Maraviroc

Brand names: Celsentri

Maraviroc is an antiretroviral CCR5 antagonist used as part of combination therapy for HIV infection in patients with detectable CCR5-tropic virus.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds the CCR5 co-receptor on the host cell surface, blocking the interaction with the viral envelope glycoprotein that CCR5-tropic HIV requires to enter the cell.

Prescribing in practice

  • A tropism test must confirm CCR5-tropic virus before use, because maraviroc is ineffective against CXCR4-tropic or dual/mixed-tropic HIV.
  • It is a CYP3A substrate, so the dose must be adjusted according to interacting drugs and current prescribing references.
  • Hepatotoxicity, sometimes preceded by allergic or systemic features, has been reported and warrants vigilance.

Monitoring

Monitor HIV viral load and CD4 count, and review liver function and for signs of hypersensitivity during treatment.

Counselling the patient

  • This medicine only works against a particular type of HIV, which is why a blood test is done first.
  • Take it consistently as part of your full HIV treatment.
  • Report any jaundice, abdominal pain or rash promptly.

Evidence & guidelines

Efficacy in treatment-experienced patients with CCR5-tropic HIV was shown in randomised controlled trials supporting its licensed use.

Reference: BHIVA; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways